N-Acetyl-DL-Leucine is an acetylated derivative of the essential amino acid leucine and a racemate
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Introduction N-acetyl-DL-leucine is an acetylated derivative of the essential amino acid leucine and a racemic mixture of enantiomers (1:1) N-acetyl-L-leucine and N-acetyl-D-leucine. N-acetyl-DL-leucine has been used in France for over 50 years for the treatment of acute vertigo and has been demonstrated to improve postural compensation in patients after vestibular neurotomy and labyrinthectomy (Leau and Ducrot, 1957; Neuzil, 2002; Viart and Vidal, 2009 ). A study of N-acetyl-L-leucine and N-acetyl-Dleucine in a rat model of unilateral labyrinthectomy revealed that N-Acetyl-L-Leucine, but not N-Acetyl-D-Leucine, is the pharmacologically active substance that improves central vestibular compensation (Gunther et al., 2015) . Furthermore, a study in a unilateral vestibular neurectomy cat model suggested N-Acetyl-L-Leucine is the active part of the racemate that leads to a significant acceleration of the vestibular compensation process, most likely through acting on vestibular nuclei (VN) neurons (Tighilet et al., 2015) .
Given that there are phylogenetic and electrophysiological similarities and close interactions between vestibular and deep cerebellar neurons, it was hypothesized that N-Acetyl-DL-Leucine may have clinical utility in the treatment of cerebellar disorders such as Niemann-Pick disease type C (NPC), for example in the reduction of ataxic symptoms, through a potentially similar mechanism observed in models of vertigo. Published studies have shown that this may be because N-acetyl-DLleucine can correct the membrane potential of hyperpolarized or depolarized vestibular neurons in a lesioned guinea pig model (Vibert and Vidal, 2001) , whereby its direct interaction with membrane phospholipids such as phosphatidylinositol 4,5-bisphosphate influenced ion channel activity (Suh and Hille, 2008) . Indeed, in observational clinical studies, treatment with N-Acetyl-DL-Leucine improved cerebellar ataxia, including in patients with the lysosomal storage disorder (LSD) NPC) (Strupp et al. 2013; Schneipp et al. 2016; Bremova et al., 2015) . However, the pharmacological mechanism of action of N-acetyl-Leucine for these disorders remains to be further clarified.
In this study, we sought to further characterize the potential therapeutic benefit of N-acetyl-DL-leucine and its enantiomers for lysosomal storage disorders such as NPC. In common with other LSDs, NPC is characterized by expansion of the endosomal/lysosomal (LE/Lys) system. Relative volume of the LE/Lys system can be measured in viable cells by flow cytometry using a commercially available fluorescent probe, LysoTracker, a fluorescent dye that is a weak base that can be trapped in the acidic environment of the lysosome (Heard et al., 2010; Lachmann et al., 2004; Wraith, 2002) . It has previously been demonstrated that increased LysoTracker fluorescence is a hallmark of NPC1 cells (te Vruchte et al., 2014) . Furthermore, this assay has been successfully applied to measure relative acidic compartment volume in B cells from a cohort of NPC patients, as well as Npc1 -/mutant mice (te Vruchte et al., 2014) . This previous study showed that measuring storage in circulating B cells mirrors progressive glycosphingolipid storage in the brain, validating the use of this peripheral cell biomarker for NPC. It is therefore expected that such a biomarker may be broadly used as a universal biomarker for this family of lysosomal storage disorders, as an aid for the initial diagnosis, monitoring disease progression, and determining response to therapies.
Based on the above background, in this study we investigated the impact of N-acetyl-DLleucine and its enantiomers using LysoTracker in non-neuron cells, including NPC null Chinese
Hamster Ovary (CHO) cells and fibroblasts derived from NPC patients. Given that the previous study reported that the N-Acetyl-L-Leucine is the active enantiomer (Gunther et al., 2015; Tighilet et al., 2015) , we also compared the effects of N-Acetyl-DL-Leucine, N-Acetyl-L-Leucine and N-Acetyl-D-Leucine on relative lysosomal volume to investigate whether this may also be relevant to the benefits observed in NPC patients.
Methods

LysoTracker staining in NPC1 Non-Neuronal Cells
Human fibroblasts from NPC1 patients were purchased from the NINDS Human Genetic Repository at the Coriell Institute (USA). Fibroblasts or wild type (WT) and NPC1-null CHO cell lines cells (Cruz et al., 2000) were grown in T25 or T75 culture flasks (Greiner Bio-One) and treated for 7 days with N-Acetyl-DL-Leucine (Molekula #73891210), N-Acetyl-L-Leucine (Sigma Aldrich #441511) or N-Acetyl-D-Leucine (Sigma Aldrich #A0876) prior to harvesting. Cells were trypsinized, 
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